Plus Therapeutics Inc (NASDAQ: PSTV) kicked off on Friday, down -6.90% from the previous trading day, before settling in for the closing price of $0.49. Over the past 52 weeks, PSTV has traded in a range of $0.16-$2.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 46.51%. While this was happening, its average annual earnings per share was recorded 78.40%. With a float of $98.84 million, this company’s outstanding shares have now reached $99.26 million.
Plus Therapeutics Inc (PSTV) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Plus Therapeutics Inc is 0.43%, while institutional ownership is 3.19%. The most recent insider transaction that took place on Aug 22 ’25, was worth 53,779. In this transaction Director of this company bought 110,000 shares at a rate of $0.49, taking the stock ownership to the 139,327 shares. Before that another transaction happened on May 15 ’25, when Company’s Director proposed sale 36,666 for $0.55, making the entire transaction worth $20,276.
Plus Therapeutics Inc (PSTV) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.37 earnings per share (EPS), higher than consensus estimate (set at -0.56) by 0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 78.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.60% during the next five years compared to 46.51% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
Take a look at Plus Therapeutics Inc’s (PSTV) current performance indicators. Last quarter, stock had a quick ratio of 1.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.23, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Looking closely at Plus Therapeutics Inc (NASDAQ: PSTV), its last 5-days average volume was 4.83 million, which is a drop from its year-to-date volume of 18.98 million. As of the previous 9 days, the stock’s Stochastic %D was 17.27%.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 27.69%, which indicates a significant increase from 1.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0627 in the past 14 days, which was lower than the 0.0800 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4627, while its 200-day Moving Average is $0.8167. However, in the short run, Plus Therapeutics Inc’s stock first resistance to watch stands at $0.4799. Second resistance stands at $0.5037. The third major resistance level sits at $0.5162. If the price goes on to break the first support level at $0.4436, it is likely to go to the next support level at $0.4311. Should the price break the second support level, the third support level stands at $0.4073.
Plus Therapeutics Inc (NASDAQ: PSTV) Key Stats
The company with the Market Capitalisation of 45.26 million has total of 99,265K Shares Outstanding. Its annual sales at the moment are 5,820 K in contrast with the sum of -12,980 K annual income. Company’s last quarter sales were recorded 1,390 K and last quarter income was 5,150 K.
